Fundraising Fox

Biotech Startups

10,023 companies tagged Biotech, with their investors and founders.

Lakewood-Amedex

Lakewood Amedex develops antimicrobial compounds, specifically Bisphosphocinยฎ formulations, designed as locally delivered bactericides and fungicides with potential medical applications. The company focuses on advancing antimicrobial technology to address infection treatment needs.

0 investors

Lamassu Pharma

0 investors

Land Medicine

0 investors

Lanier Biotherapeutics

Lanier Biotherapeutics is a biotherapeutics company. The page provides no specific detail about its products, pipeline, or target market.

0 investors

Lannett

0 investors

Lapix Therapeutics

LAPIX Therapeutics is a clinical-stage biopharmaceutical company developing an orally administered, non-immunosuppressive T-cell engager therapy for people with autoimmune diseases. Its lead therapeutic, LPX-TI641, is an antigen-agnostic TIM pathway agonist targeting TIM-3 and TIM-4 receptors to restore immune balance across a range of autoimmune conditions.

0 investors

Larimar Therapeutics

0 investors

Lattice Biologics

0 investors

Lattice Biotech

0 investors

Lattice Therapeutics

0 investors

Launchpad Therapeutics, Inc.

0 investors

Lavior

0 investors

Laxco

Laxco is a supplier of laboratory and scientific instruments, including life science and digital imaging products. It serves laboratory and research markets.

0 investors

Laxmi Therapeutic Devices

Laxmi Therapeutic Devices develops wearable diabetes management technology to improve patient health outcomes and time in range.

0 investors

Layka Bio

0 investors

Lazarus 3D

0 investors

Lazurite

0 investors

Lazzaro Medical

0 investors

Leading Biosciences

0 investors

LeafBio

0 investors

Leafline Labs

0 investors

Legacy Ventures

0 investors

Lennham Pharmaceuticals

Lennham applies deuterium chemistry to modify the metabolic and pharmacokinetic properties of drug compounds, aiming to develop pharmaceutical products with improved profiles and patent protection. The company identifies compounds that could benefit from such modification and advances candidates with clinical and commercial potential.

0 investors

Lenticular Research Group

0 investors

Other sectors & tags